Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management
Obesity

Obesity is a chronic, relapsing, neurobehavioural disease with metabolic, biomechanical and psychosocial health consequences. Assessing and treating obesity is a common requirement in primary care consultations. Even when changes are gradual, small and stepwise, they can have long-lasting positive effects. This article by Ole Schmiedel provides evidence-based tools for the successful management of people with obesity
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
1. Upadhyay J, Farr O, Perakakis N, et al. Obesity as a disease. Med Clin North Am 2018;102(1):13–33.
2. Ministry of Health. Annual Data Explorer 2020/21: New Zealand Health Survey. 2021. https://minhealthnz.shinyapps.io/nz-health-survey-2020-21-annual-data-explorer/
3. Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009;373(9669):1083–96.
4. Srivastava G, Kushner RF, Apovian CM. Use of the historial weight trajectory to guide an obesity-focused patient encounter. In: Feingold KR, Anawalt B, Boyce A, et al (editors). Endotext. South Dartmouth, MA: MDText.com, Inc; 2000.
5. Ministry of Health. Clinical Guidelines for Weight Management in New Zealand Adults. Wellington, NZ: Ministry of Health; 2017.
6. Ministry of Health. Clinical Guidelines for Weight Management in New Zealand Children and Young People. Wellington, NZ: Ministry of Health; 2016.
7. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015;100(2):342–62.
8. Taylor T, Wang Y, Rogerson W, et al. Attrition after acceptance onto a publicly funded bariatric surgery program. Obes Surg 2018;28(8):2500–07.
9. Cawley J, Biener A, Meyerhoefer C, et al. Direct medical costs of obesity in the United States and the most populous states. J Manag Care Spec Pharm 2021;27(3):354–66.
10. Cawley J, Meyerhoefer C, Biener A, et al. Savings in medical expenditures associated with reductions in body mass index among US adults with obesity, by diabetes status. Pharmacoeconomics 2015;33(7):707–22.
Table 2: Sharma A, Kushner R. A proposed clinical staging system for obesity. Int J Obes 2009;33:289–95.